Metoglin Tablets 2.5/850 mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
You&Life Science Co., Ltd.
MFDS item code 201907071 · Approved 2019.10.04
This product's status changed to Expired on 2024.10.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood sugar control in adult patients with type 2 diabetes. It supports dietary and exercise regimens and is administered when blood sugar control is difficult on its own or when there is no previous experience with diabetes medication. Additionally, it is used in conjunction with metformin monotherapy or with metformin combined with other medications (sulfonylurea, insulin, empagliflozin) if blood sugar control is still insufficient. Thus, it effectively enhances blood sugar control in a variety of treatment combinations.
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose of this drug is 1 tablet of this drug 2.5/500 mg twice daily, which may be increased to 1 tablet of this drug 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start with their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this drug should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this drug is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this drug should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this drug is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, provided that the following dose adjustments are made. The starting dose of metformin is 500mg or 850mg once daily; therefore, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin. (See Precautions for Use, 1. Do not administer to the following patients).
This medication may cause a rare complication known as lactic acidosis; therefore, it should not be used in patients with impaired kidney function or heart disease. Furthermore, it should not be administered to patients allergic to any component of this medication, those with type 1 diabetes, or women who are pregnant or breastfeeding. When used with other diabetes medications that pose a risk of hypoglycemia, careful monitoring of blood sugar changes is necessary, and dosage adjustments may be needed. Elderly patients with reduced kidney function or those with acute illnesses should definitely consult their physician before taking this medication. If receiving iodine contrast agents used in radiographic examinations, it is necessary to discontinue this medication for a certain period before and after the examination and to check kidney function. Patients scheduled for surgery should stop this medication 48 hours prior to the procedure and resume taking it only after normal recovery of kidney function post-surgery. This medication may cause side effects such as gastrointestinal disturbances, abdominal pain, and diarrhea; if symptoms are severe, consulting a physician is advisable. There is a risk of Vitamin B12 deficiency, so patients on long-term use should regularly check their Vitamin B12 levels. If symptoms of acute pancreatitis or bullous pemphigoid appear, immediately discontinue use and inform healthcare professionals. Women planning to become pregnant or already pregnant should consider insulin therapy instead of this medication, and it is advisable for breastfeeding women to avoid this medication as well. It is not recommended for children and those under 10 years of age due to the lack of safety and efficacy data. In cases of overdose, serious side effects like lactic acidosis may occur, so it is crucial to adhere strictly to the prescribed dosage and to seek immediate medical attention in case of abnormal symptoms.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be kept in a tightly closed container. It is best to store it at room temperature between 1 to 30 degrees Celsius.
Bilateral convex oval film-coated tablets in bright orange color
60 tablets (10 tablets/PTP packaging x 6 units)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
You&Life Science Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.